Opportunity for an Ear Drop NDA

September 11, 2015

The FDA’s announcement this summer that it would take enforcement action against several unapproved formulations of ear drops provides a great opportunity for a pharmaceutical company that would like to develop an NDA for this type of product.

Unapproved prescription products containing the following ingredients are affected by this action:

  • Benzocaine
  • Benzocaine and antipyrine
  • Benzocaine, antipyrine, and zinc acetate
  • Benzocaine, chloroxylenol, and hydrocortisone
  • Chloroxylenol and pramoxine
  • Chloroxylenol, pramoxine, and hydrocortisone

Of course, FDA's action does not impact approved prescription products or legally marketed over-the-counter (OTC) products.

It is likely that the 505(b)(2) path could be followed for one of these compounds. Since these therapies have been available for decades it is possible that safety and efficacy could be demonstrated based on available relevant literature, thereby minimizing or eliminating the necessity of conducting clinical trials.

The Weinberg Group has assisted a number of clients in obtaining literature-based NDA approvals. The typical process is:

  • Development of Regulatory Strategy
  • Pre-IND Meeting
  • PREA Strategy
  • Pre-NDA Meeting
  • Development of NDA
  • NDA Submission
  • Approval Process/Dialogue with FDA
  • Approval

If you need assistance in developing an NDA for one of these ear drop formulations, or any other compound, please contact us.




Agency Alerts General Regulatory Three piles of pills

November 1, 2018

FDA Encourages Development of Novel Drugs for Rare Diseases with Draft Guidance Regarding the Role of Pre-IND Meetings

On Monday, October 12th, FDA issued a draft guidance regarding the role of Pre-IND Meetings in the development of drugs to treat rare diseases. The document, entitled "Rare Diseases: Early Drug...

Read the Full Article
General Regulatory Drug Approval

October 5, 2021

Four Benefits of Requesting an FDA Pre-IND Meeting

Although not required, a Pre-IND Meeting is a critical milestone, one that is highly recommended by the FDA. The goal of the meeting is to receive general agreement from FDA that your drug...

Read the Full Article
FDA NDA

May 18, 2022

FDA Releases Draft Guidance for Industry on Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies

The FDA’s Office of Clinical Pharmacology within the Office of Translational Sciences released a new draft guidance document that, for the first time, clearly addresses the FDA’s recommendations and...

Read the Full Article